近日，丹麦制药巨头诺和诺德公布的第三季度财报显示，诺和诺德业绩实现同比增长5%，这包括总销售额和GLP-1产品线。然而，环比业绩较前两季度下降，主力产品诺和盈的销售额不及预期。为维持市场份额和克服增长放缓，诺和诺德选择重拳破局：豪掷千金，决定将拥有前景广阔的GLP-1技术平台和产品管线的Metsera收入囊中。然而，对Metsera志在必得的还有在该领域进展不顺的辉瑞。对此，双方在两周之内交锋迅速...
Source Link近日，丹麦制药巨头诺和诺德公布的第三季度财报显示，诺和诺德业绩实现同比增长5%，这包括总销售额和GLP-1产品线。然而，环比业绩较前两季度下降，主力产品诺和盈的销售额不及预期。为维持市场份额和克服增长放缓，诺和诺德选择重拳破局：豪掷千金，决定将拥有前景广阔的GLP-1技术平台和产品管线的Metsera收入囊中。然而，对Metsera志在必得的还有在该领域进展不顺的辉瑞。对此，双方在两周之内交锋迅速...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.